In a landmark deal announced last week, President Donald Trump negotiated dramatically lower costs for weight-loss drugs produced by pharmaceutical giants Eli Lilly and Novo Nordisk, which could ...

Unprecedented surge in Irish exports this year was almost entirely driven by shipments of drug ingredients for Eli Lilly ...

Novo Nordisk and Eli Lilly deny partnership with Mangoceuticals for weight-loss drugs, causing Mangoceuticals' shares to ...

Novo Nordisk A/S growth is driven by global obesity drug demand, robust pipeline development and manufacturing scale. Read ...

Is Trump's icy silence revealing a family feud? Critics are abuzz after a strange pause and topic shift in response to a ...

Novo Nordisk faces a shareholder backlash on Friday as the Danish drugmaker's minority investors prepare a protest vote ...

Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth ...

Both Eli Lilly and Novo Nordisk are denying a telehealth company’s claim of having struck partnerships with the two companies ...

Novo Nordisk (NVO) and Eli Lilly (LLY) do not have a weight-loss drug partnership with telehealth website Mangoceuticals (MGRX), spokespeople for ...

Pfizer enters the lucrative weight-loss drug market with a massive $10 billion Metsera acquisition, targeting a $150-200 ...

WeightWatchers intends to offer Novo Nordisk’s pill version of Wegovy if it makes its US debut next year following potential ...

Weight-loss drug developer Zealand Pharma said it halted work on an early-stage obesity treatment candidate to focus on more promising programs, including one for which it teamed up with Swiss giant ...